The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from GlobeNewswire (a Nasdaq OMX company)

Cardiome Notes Updated Guidelines From European Society of Cardiology Now Include Brinavess(TM) (Vernakalant) for Infusion

Monday, September 10, 2012

Cardiome Notes Updated Guidelines From European Society of Cardiology Now Include Brinavess(TM) (Vernakalant) for Infusion05:45 EDT Monday, September 10, 2012VANCOUVER, B.C., Sept. 10, 2012 (GLOBE NEWSWIRE) -- Cardiome Pharma Corp. (Nasdaq:CRME) (TSX:COM) today noted that the European Society of Cardiology (ESC) has issued updated treatment guidelines for the treatment of adult patients with recent on-set atrial fibrillation, a type of irregular heartbeat. The focused update now includes the intravenous (IV) formulation of BrinavessTM (vernakalant), among other treatments, when pharmacologic cardioversion is preferred, as first line therapy for the cardioversion of atrial fibrillation to normal sinus rhythm in patients with no or moderate structural heart disease. The new guidelines were presented as part of the annual meeting of the European Society of Cardiology Congress in Munich on August 28, 2012 and have been published in the European Heart Journal (Camm et al., (2012), European Heart Journal August 24, 2012). http://www.escardio.org/guidelines-surveys/esc-guidelines/GuidelinesDocuments/Guidelines_Focused_Update_Atrial_Fib_FT.pdf "I am pleased with the new ESC guidelines that include a discussion of the results of six clinical trials of BrinavessTM," stated William Hunter, M.D., Interim CEO of Cardiome. "The inclusion of BrinavessTM in these updated guidelines gives us important information to share with the medical community in Europe." BrinavessTM is approved in the European Union for the rapid conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults: for non-surgery patients with AF of seven days or less and for post-cardiac surgery patients with AF of three days or less. BrinavessTM is not approved for use in the United States or Canada. Cardiome has licensed worldwide marketing rights for the product to a subsidiary of Merck (known as MSD outside of the United States and Canada) and the commercial introduction of the product is underway in Europe, Latin America and other global markets.About Cardiome Pharma Corp. Cardiome Pharma Corp. is a biopharmaceutical company dedicated to the discovery, development and commercialization of new therapies that will improve the health of patients around the world. Cardiome has one marketed product, BrinavessTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.Forward-Looking Statement Disclaimer Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe," "may," "plan," "will," "estimate," "continue," "anticipate," "intend," "expect" and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Risks, uncertainties and factors that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks, uncertainties and factors related to the fact that: we, together with our collaborative partners, may not be able to successfully develop all or any of our current or future products and may not be able to obtain regulatory approval in targeted indications for our current or future products in all markets; we may not achieve or maintain profitability; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital as and when required; we depend on our collaborative partners to perform their obligations under licensing or other collaborative agreements; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; any of our products that obtain regulatory approval will be subject to extensive post-market regulation that may affect sales, marketing and profitability; any of our products that are successfully developed may not achieve market acceptance; we rely on third parties for the continued supply and manufacture of our products and have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters, including with respect to our ability to protect our intellectual property; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.CONTACT: Cardiome Investor Relations (604) 676-6993 or Toll Free: 1-800-330-9928 Email: ir@cardiome.com